Drugs / NanoFlu
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03293498 | Sep 2017 → Mar 2018 | influenza | Novavax | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03658629 | Sep 2018 → Apr 2019 | influenza | Novavax | Terminated | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT04120194 | Oct 2019 → Oct 2020 | influenza | Novavax | Completed | Met primary |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2022-05-09 | Novavax | Results Novavax Reports First Quarter 2022 Financial Results and Operational Highlights novavax.com ↗
Immune response confirmed in stand-alone influenza vaccine candidate and CIC vaccine candidate with potential path forward for both |
| 2021-12-02 | Novavax | Results Novavax Statement on Omicron Variant Response novavax.com ↗
Novavax’ Phase 3 trial of NanoFlu™, our quadrivalent nanoparticle vaccine candidate against seasonal influenza, demonstrated the strong role our proprietary Matrix-M™ adjuvant can play in addressing rapid viral genetic drift. |
| 2021-09-23 | Novavax | Results Results from Novavax NanoFlu Influenza Vaccine Phase 3 Clinical Trial Published in The Lancet Infectious Diseases novavax.com ↗
In the complete analysis, NanoFlu was well-tolerated and produced significantly enhanced humoral and cellular immune responses versus the comparator vaccine. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-05-09 | Novavax | Novavax Reports First Quarter 2022 Financial Results and Operational Highlights novavax.com ↗ |
| 2021-12-02 | Novavax | Novavax Statement on Omicron Variant Response novavax.com ↗ |
| 2021-09-23 | Novavax | Results from Novavax NanoFlu Influenza Vaccine Phase 3 Clinical Trial Published in The Lancet Infectious Diseases novavax.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NanoFlu | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04120194 ↗ |
| Known as | Quad-NIV | “Biological: NanoFlu (Quad-NIV)” NCT03658629 ↗ |
| Modality | Vaccine | “recombinant hemagglutinin (HA) quadrivalent nanoparticle influenza vaccine (qNIV)” PMID 33146720 ↗ Dec 2021 |
| Route | Intramuscular | “administered an IM injection of NanoFlu” NCT03293498 ↗ |